Background Long term efficacy of raltegravir (RAL)-including regimens in highly pre-treated HIV-1-infected patients has been demonstrated in registration trials. However, few studies have assessed durability in routine clinical settings. Methods Antiretroviral treatment-experienced patients initiating a RAL-containing salvage regimen were enrolled. Routine clinical and laboratory follow-up was performed at baseline, week 4, 12, and every 12 weeks thereafter. Data were censored at week 96. Results Out of 320 patients enrolled, 292 (91.25%) subjects maintained their initial regimen for 96 weeks; 28 discontinued prematurely for various reasons: death (11), viral failure (8), adverse events (5), loss to follow-up (3), consent withdrawal (1). Eight among these 28 subjects maintained RAL but changed the accompanying drugs. The mean CD4+ T-cell increase at week 96 was 227/mm3; 273 out of 300 patients (91%), who were still receiving RAL at week 96, achieved viral suppression (HIV-1 RNA <50 copies/mL). When analyzing the immuno-virologic outcome according to the number of drugs used in the regimen, 2 (n = 45), 3 (n = 111), 4 (n = 124), or >4 (n = 40), CD4+ T-cell gain was similar across strata: +270, +214, +216, and +240 cells/mm3, respectively, as was the proportion of subjects with undetectable viral load. Laboratory abnormalities (elevation of liver enzymes, total cholesterol and triglycerides) were rare, ranging from 0.9 to 3.1%. The mean 96-week total cholesterol increase was 23.6 mg/dL. Conclusions In a routine clinical setting, a RAL-based regimen allowed most patients in salvage therapy to achieve optimal viral suppression for at least 96 weeks, with relevant immunologic gain and very few adverse events.
References
[1]
Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, et al. (2007) Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369: 1261–1269.
[2]
Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, et al. (2010) Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 50 (4): 605–612.
[3]
Wittkop L, Breilh D, Da-Silva D, Duffau P, Mercié P, et al. (2009) Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy, ANRS CO3 Aquitaine Cohort. J Antimicrob Chemother 63 (6): 1251–1255.
[4]
Teague A, Scott C, Bower M, Gazzard B, Nelson M, et al. (2010) A single-center cohort experience of raltegravir in salvage patients failing therapy. J Acquir Immune Defic Syndr 53(5): 666–667.
[5]
Engsig FN, Gerstoft J, Kronborg G, Larsen GS, Pedersen G, et al. (2010) Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. Clinical Epidemiology 2: 145–151.
[6]
Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, et al. (2010) Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients. Scand J Infect Dis 42 (6–7): 527–532.
[7]
Nozza S, Galli L, Visco F, Soria A, Canducci F, et al. (2010) Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. AIDS 24 (6): 924–928.
[8]
Yazdanpanah Y, Fagard C, Descamps D, Taburet AM, Colin C, et al. (2009) High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis 49 (9): 1441–1449.
[9]
Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, et al. (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9 (1): 40–53.
[10]
Masiá M, Enríquez R, Sirvent A, Gutiérrez F (2010) Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution. J Infect 61: 189–190.
[11]
Reiss KA, Bailey JR, Pham PA, Gallant JE (2010) Raltegravir-induced cerebellar ataxia. AIDS 24: 2757–2761.
[12]
CTCAE website. Accessed 2010 Jan 07.
[13]
Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Accessed 2010 Jan 07.
[14]
Fagard C, Colin C, Charpentier C, Rami A, Jacomet C, et al. (2012) Long-term efficacy and safety of raltegravir, etravirine and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 Trio Trial. J Acquir Immune Defic Syndr 59 (5): 489–493.
[15]
Vispo E, Mena A, Maida I, Blanco F, Cordoba M, et al. (2010) Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 65 (3): 543–547.
[16]
Young B, Vanig T, Dejesus E, Hawkins T, St Clair M, et al. (2010) A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-na？ve HIV-1-infected patients: 48-week results of the SHIELD trial. HIV Clin Trials 11(5): 260–269.
[17]
Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, et al. (2010) Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 24 (11): 1697–1707.
[18]
Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, et al. (2003) Impact of HIV infection and HAART on serum lipids in men. JAMA 289 (22): 2978–2982.
[19]
De Socio GV, Bonfanti P, Ricci E, Orofino G, Madeddu G, et al. (2008) Cholesterol levels in HIV-HCV infected patients treated with lopinavir/r: results from the SCOLTA project. Biomed Pharmacother 62 (1): 16–20.
[20]
Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF (2009) Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection? J Acquir Immune Defic Syndr 50 (2): 233–234.
